anonymous
Guest
anonymous
Guest
What happens now that we have bought the Derm division from Bayer?
Is this great strategic move on our part.
Absolutely! All those products will produce revenue for LEO to build up more money to better launch Tralo and other pipeline drugs. Doesn't matter if they have been around for a while, they are still profitable and hold a strong market share in their disease state. Good move!